Patient characteristics
Characteristic . | Data . |
|---|---|
| Sex, no. (%) | |
| Female | 38 (57.6) |
| Male | 28 (42.4) |
| Age, y, median (range) | 57 (31-80) |
| Disease duration, mo, median (range) | 30 (0-190) |
| Disease phase, no. (%) | |
| Chronic | 20 (30.3) |
| Accelerated | 27 (40.1) |
| Clonal cytogenetic evolution only | 10 (15.2) |
| Blastic | 19 (28.8) |
| Clonal cytogenetic evolution, no. (%)† | 26 (39.3) |
| Prior therapy, no. (%) | |
| Hydroxyurea | 51 (77.3) |
| Interferon-α | 37 (56.1) |
| Cytarabine | 18 (27.3) |
| Topoisomerase II inhibitors | 11 (16.7) |
| 6-Mercaptopurine | 6 (9.1) |
| 6-Thioguanine | 6 (9.1) |
| Busulfan | 5 (7.8) |
| Melphalan | 3 (4.5) |
| Other* | 4 (6.1) |
| None | 4 (6.1) |
Characteristic . | Data . |
|---|---|
| Sex, no. (%) | |
| Female | 38 (57.6) |
| Male | 28 (42.4) |
| Age, y, median (range) | 57 (31-80) |
| Disease duration, mo, median (range) | 30 (0-190) |
| Disease phase, no. (%) | |
| Chronic | 20 (30.3) |
| Accelerated | 27 (40.1) |
| Clonal cytogenetic evolution only | 10 (15.2) |
| Blastic | 19 (28.8) |
| Clonal cytogenetic evolution, no. (%)† | 26 (39.3) |
| Prior therapy, no. (%) | |
| Hydroxyurea | 51 (77.3) |
| Interferon-α | 37 (56.1) |
| Cytarabine | 18 (27.3) |
| Topoisomerase II inhibitors | 11 (16.7) |
| 6-Mercaptopurine | 6 (9.1) |
| 6-Thioguanine | 6 (9.1) |
| Busulfan | 5 (7.8) |
| Melphalan | 3 (4.5) |
| Other* | 4 (6.1) |
| None | 4 (6.1) |